Novel diagnostic tools and solutions for multiple sclerosis treatment: A patent review (2009-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 8, 2015, Pages 873-884

  Papini, Anna Maria ^a   König, Enrico ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Toscana Biomarkers Srl   (Italy)

Author keywords

Autoimmunity; Circulatory abnormality; Inflammation; Oligodendropathy; Redox processes

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOETIN 2 INHIBITOR; BETA INTERFERON; BIOLOGICAL MARKER; CYCLOSPORIN A; DACLIZUMAB; DAPTOMYCIN; GELSOLIN; IDEBENONE; MURAMYL DIPEPTIDE; MYELIN BASIC PROTEIN; OXADIAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TERIFLUNOMIDE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; HEMODYNAMICS; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; INFLAMMATION; MULTIPLE SCLEROSIS; OXIDATION REDUCTION REACTION; PATENT; PATHOGENESIS; PROTEOMICS; REVIEW; VEIN BLOOD FLOW; ANIMAL; DRUG APPROVAL; DRUG DESIGN; PATHOPHYSIOLOGY; PROCEDURES; UNITED STATES;

ANIMALS; DRUG APPROVAL; DRUG DESIGN; HUMANS; MULTIPLE SCLEROSIS; PATENTS AS TOPIC; PROTEOMICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84937197241     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1043267     Document Type: Review

References (93)

1. World Health Organization. Atlas multiple sclerosis resources in the world 2008. WHO Press; Geneva, Switzerland: 2008
2. Johnson KP. The remarkable story of Copaxone. An approach to the treatment of multiple sclerosis. DiaMedica Publishing; New York: 2010
3. Charcot JM. Histology of "sclerose en plaque" (in French). Gazette Hosp (Paris) 1868;41:554-66
4. Holliday SM, Benfield P. Interferonbeta-1a. BioDrugs 1997;8(4):317-30
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43(4):655-61
6. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Eng J Med 1987;317:408-14
7. Supreme court sides with Teva in drug dispute. New York Times. 20. 01. 2015
8. Aharoni R, Teitelbaum D, Sela M, et al. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Nat Acad Sci USA 1997;94(20):10821-6
9. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2008;71(10):766-73
10. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003;61(10):1332-8
11. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8
12. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: A geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain 1999;122(10):1941-50
13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis. Neurology 1996;46:907-11
14. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003;206(2):135-7
15. Leary SM, Thompson AJ. Primary progressive multiple sclerosis. CNS Drugs 2005;19(5):369-76
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121-7
17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revision to the McDonald criteria. Ann Neurol 2011;69(2):292-302
18. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58(2):840-6
19. Nakahara J, Maeda M, Aiso S, et al. Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 2012;42:26-34
20. Miljkovic D, Spasojevic I. Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2013;19(18):2286-334
21. Podbielska M, Hogan EL. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult Scler 2009;15:1011-29
22. Balashov KE, Khoury SJ, Hafler DA, et al. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995;95(6):2711-19
23. Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4 +CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35(11):3343-52
24. Misu T, Onodera H, Fujihara K, et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 2001;114(1-2):207-12
25. Ziemssen T, Kümpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 2002;125(11):2381-91
26. Alcaro MC, Lolli F, Migliorini P, et al. Peptides as autoimmune diseases antigenic probes. Chemistry Today 2007;25(3):14-16
27. Pandey S, Alcaro MC, Scrima M, et al. Designed glucopeptides mimetics of myelin protein epitopes as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis. J Med Chem 2012;55(23):10437-47
28. Pandey S, Dioni I, Lambardi D, et al. Alpha actinin is specifically recognized by multiple sclerosis autoantibodies isolated using an N-glucosylated peptide epitope. Mol Cell Proteomics 2013;12:277-82
29. Panza F, Pratesi F, Valoriani D, et al. Immunoglobulin G subclass profile of anticitrullinated peptide antibodies specific for Epstein Barr Virus-derived and histone-derived citrullinated peptides. J Rheumatol 2014;41(2):407-8
30. Papini AM. The use of posttranslationally modified peptides for detection of biomarkers of immunemediated diseases. J Peptide Sci 2009;15:621-8
31. Pratesi F, Dioni I, Tommasi C, et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheumatic Dis 2013;73:1414-22
32. Carotenuto A, D'Ursi AM, Nardi E, et al. Conformational analysis of a glycosylated human myelin oligodendrocyte glycoprotein peptide epitope able to detect antibody response in multiple sclerosis. J Med Chem 2001;44:2378-81
33. Lolli F, Mazzanti B, Pazzagli M, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 2005;167:131-7
34. Lolli F, Mulinacci B, Carotenuto A, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Nat Acad Sci USA 2005;102(29):10273-8
35. Baka Z, Gyorgy B, Geher P, et al. Citrullination under physiological and pathological conditions. Joint Bone Spine 2012;79:431-6
36. de Seze J, Duducquoi S, Lefranc D, et al. IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J Neuroimmunol 2001;117(1-2):149-55
37. Kim JK, Mastronardi FG, Wood DD, et al. Multiple Sclerosis: An important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2003;2:453-62
38. Moscarello M, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007;32(2):251-6
39. Tranquill LR, Cao L, Ling NC, et al. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult Scler 2000;6(4):220-5
40. Zamboni P, Menegatti E, Bartolomei I, et al. Intracranial venous haemodynamics in multiple sclerosis. Cur Neurov Res 2007;4:252-8
41. Zamboni P. System for diagnosing multiple sclerosis. WO2009107152; 2008
42. Barreto AD, Brod SA, Bui TT, et al. Chronic cerebrospinal venous insufficiency: case-control neurosonography results. Ann Neurol 2013;73(6):721-8
43. ElSankari S, Baledent O, Pesch VV, et al. Concomitant analysis of arterial, venous, and CSF flows using phasecontrast MRI: A quantitative comparison between MS patients and healthy controls. J Cereb Blood Flow Metab 2013;33:1314-21
44. Brown JE, Margolis MP, Gaddis ML. Diagnostic and therapeutic methods, devices, and systems for multiple sclerosis, deep vein thrombosis, and pulmonary embolism patients. WO092444; 2012
45. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 1979;281:583-6
46. Bucki R, Levental I, Kulakowska A, et al. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008;9(6):541-51
47. Mintzer E, Sargsyan H, Bittman R. Lysophosphatidic acid and lipopolysaccharide bind to the PIP2-binding domain of gelsolin. Biochim Biophys Acta 2006;1758(1):85-9
48. Stossel TP, Lee P-S, Dittel B, et al. Use of gelsolin to treat multiple sclerosis and to diagnose neurological disease. US8440662; 2013
49. Lovato L, Cianti R, Gini B, et al. Transketolase and 2, 3-cyclic-nucleotide 3-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in Multiple Sclerosis patients. Mol Cell Proteomics 2008;7:2337-49
50. Bevilacqua M, Tryon V, Bankaitis-Davis D, et al. Gene expression profiling for identification, monitoring and treatment of multiple sclerosis. WO2008008487; 2006
51. Somers V, Stinissen P. Biomarkers for multiple sclerosis. WO2008125651; 2007
52. Ibrahim S. Mononucleotide polymorphisms of the human chromosome 4 in the inositol polyphosphate 4-phosphatase type II gene (INPP4b gene) for diagnosing or prediagnosing multiple sclerosis. WO2011101466; 2010
53. Monson N. VH4 codon signature for multiple sclerosis. WO2010011894; 2008
54. Koelsch K, Zheng NY, Zhang Q, et al. Mature B cells class switched to IgD are autoreactive in healthy individuals. J Clin Invest 2007;117(6):1558-65
55. Klinger E, Tessler S, Hussein H, et al. Methods for treating multiple sclerosis using antisense oligonucleotides. US8759314; 2014
56. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75
57. Wraith D, Streeter H. Compositions comprising myelin basic protein peptides and medical uses thereof. EP2211892; 2011
58. Buckel P, Jacob U. FC gamma receptor for the treatment of B cell mediated multiple sclerosis. WO2010026168; 2008
59. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-12
60. Sheridan III JP. Methods for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients. EP2425250; 2014
61. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A Phase II, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-90
62. Kirchner J, Mustelin TM. ANG-2 inhibition to treat multiple sclerosis. WO2009158432; 2008
63. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skinstructure infections. Clin Infect Dis 2004;38(12):1673-81
64. Keith D, Govardhan C, Khalaf N. Methods for preparing purified daptomycin. WO2002056829; 2001
65. Guarnaccia JB. Daptomycin for multiple sclerosis. WO2011043788; 2009
66. Gelder FB, Webster GA. Composition and methods for treatment of multiple sclerosis. WO2010147484; 2009
67. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's Disease. J Biol Chem 2003;278(8):5509-12
68. Martinon F, Agostini L, Meylan E, et al. Identification of bacterial muramyl dipeptide as activator of the NALP3/ cryopyrin inflammasome. Cur Biol 2004;14(21):1929-34
69. Rustin P, Rotig A. Quinone derivatives for treating or preventing diseases associated with iron overload. EP0402703; 1998
70. Zs-Nagy I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: A review. Arch Gerontol Geriatr 1990;11(3):177-86
71. Meier T, Bielekova B, McFarland HF. Quinone derivative 2, 3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1, 4-benzoquinone for the treatment of primary progressive multiple sclerosis. WO2010124713; 2009
72. Lukashev ME, O'Neill G. Composition and uses for treating multiple sclerosis. WO2008097596; 2007
73. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
74. Bombrun A, Schwarz M, Crosigniani S, et al. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. EP2183224; 2013
75. Muzerelle M, Quattropani A, Montagne C, et al. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis. US8741923; 2014
76. Bykovskaia SN, Eliseeva DD, Zavalishin IA. Treatment method for relapsing-remitting multiple sclerosis. WO2014003605; 2012
77. Brentzel HJ, Lopez-Bresnahan M, Ammoury N. Combination of interferonbeta and a cladribine regimen for treating multiple sclerosis. EP2026832; 2012
78. Selby R, Brandwein J, O'Connor P. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can J Neurol Sci 1998;25(4):295-9
79. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting Multiple Sclerosis. Proc Assoc Am Physicians 1999;111(1):35-44
80. Rice GPA, Filippi M, Comi G, et al. Cladribine and progressive MS. Clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54(5):1145-55
81. Bryrnes W, Douillet P, Frangin G. Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis. WO2011005907; 2009
82. Wettstein J. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis. US6794410; 2001
83. Forte M, Bourdette D. Cyclic undecapeptides and derivatives as multiple sclerosis therapies. EP2195009; 2014
84. Giovannoni G, Munschauer FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:465-9
85. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
86. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4):438-46
87. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392-9
88. Alcaro MC, Papini AM. Contribution of peptides to multiple sclerosis research. Biopolymers 2006;84:349-67
89. Sospedra M, Martin R. Immunology of Multiple Sclerosis. Ann Rev Immunol 2005;23:683-747
90. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Cur Opin Neurol 1999;12(3):309-21
91. Vergelli M, Mazzanti B, Traggiai E, et al. Short-term evolution of autoreactive T cell repertoire in multiple sclerosis. J Neurosci Res 2001;66(3):517-24
92. McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007;8:913-19
93. Lucchinetti C, Brück W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001;14(3):259-69